@GiulioZuccoliMD @DrJosephMaroon It is quite disappointing that there was not much discussion about the numerous confounding factors and limitations of this case. When considering multiple sources & diving into details, it is not strongly supported by
1,512 followers
1,512 followers
Why slow progression? The patient has two mutations that drastically favor survival & progression outcomes: an IDH1 mutation and loss of ATRX. His younger age is another key factor. Survival at 100 months (just over 8 years) is around 20-40% https://
5,512 followers
//ATRX retention in IDH1/2 mutant tumors was strongly associated with LOH 1p/19q and oligodendroglioma histology (p < 0.0001). // https://t.co/zZ7yVsHs2R
226 followers
RT @RomainPerbet: ATRX immunostaining predicts IDH and H3F3A status in gliomas https://t.co/0KcZhsru14